Nanomaterials as potential transporters of HDAC inhibitors

Kumar, 2019, Epigenetic Dysregulation at the Crossroad of Women's Cancer, Cancers (Basel), 11, 10.3390/cancers11081193 Muntean, 2009, Epigenetic dysregulation in cancer, Am J Pathol, 175, 1353, 10.2353/ajpath.2009.081142 West, 2014, New and emerging HDAC inhibitors for cancer treatment, J Clin Invest, 124, 30, 10.1172/JCI69738 Yoon, 2016, HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases, Chonnam Med J, 52, 1, 10.4068/cmj.2016.52.1.1 Garmpi, 2018, Histone deacetylase inhibitors as a new anticancer option: How far can we go with expectations? delivery systems, J BUON, 23, 846 De Souza, 2015, HDAC Inhibitors as Novel Anti-Cancer Therapeutics, Recent Pat Anticancer Drug Discov, 10, 145, 10.2174/1574892810666150317144511 Hirata, 2018, New 5-Aryl-Substituted 2-Aminobenzamide-Type HDAC Inhibitors with a Diketopiperazine Group and Their Ameliorating Effects on Ischemia-Induced Neuronal Cell Death, Sci Rep, 8, 1400, 10.1038/s41598-018-19664-9 Gryder, 2012, Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed, Future Med Chem, 4, 505, 10.4155/fmc.12.3 Benedetti, 2015, Targeting Histone Deacetylases in Diseases: Where Are We?, Antioxidants & Redox Signaling, 23, 99, 10.1089/ars.2013.5776 Clawson, 2016, Histone deacetylase inhibitors as cancer therapeutics, Annals of Translational Medicine, 4(15) Xu, 2007, Histone deacetylase inhibitors: molecular mechanisms of action, Oncogene, 26, 5541, 10.1038/sj.onc.1210620 Suraweera, 2018, Combination Therapy With Histone Deacetylase Inhibitors (HDACi) for the Treatment of Cancer: Achieving the Full Therapeutic Potential of HDACi, Frontiers in Oncology, 8, 10.3389/fonc.2018.00092 Denis, 2015, Histone deacetylase inhibitor-polymer conjugate nanoparticles for acid-responsive drug delivery, Eur J Med Chem, 95, 369, 10.1016/j.ejmech.2015.03.037 Vansteenkiste, 2008, Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer, Invest New Drugs, 26, 483, 10.1007/s10637-008-9131-6 Peer, 2007, Nanocarriers as an emerging platform for cancer therapy, Nat Nanotechnol, 2, 751, 10.1038/nnano.2007.387 Ngoune, 2016, Accumulating nanoparticles by EPR: A route of no return, J Control Release, 238, 58, 10.1016/j.jconrel.2016.07.028 Alp, 2019, Starch nanoparticles for delivery of the histone deacetylase inhibitor CG-1521 in breast cancer treatment, Int J Nanomedicine, 14, 1335, 10.2147/IJN.S191837 Din, 2017, Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors, Int J Nanomedicine, 12, 7291, 10.2147/IJN.S146315 Mitragotri, 2014, Organic nanoparticles for drug delivery and imaging, Mrs Bulletin, 39, 219, 10.1557/mrs.2014.11 Ma, 2015, Inorganic nanocarriers for platinum drug delivery, Materials Today, 18, 554, 10.1016/j.mattod.2015.05.017 Zhang, 2008, Self-assembled lipid--polymer hybrid nanoparticles: a robust drug delivery platform, ACS Nano, 2, 1696, 10.1021/nn800275r Ling, 2010, Development of novel self-assembled DS-PLGA hybrid nanoparticles for improving oral bioavailability of vincristine sulfate by P-gp inhibition, Journal of Controlled Release, 148, 241, 10.1016/j.jconrel.2010.08.010 Zheng, 2015, Lipid-Polymer Nanoparticles for Folate-Receptor Targeting Delivery of Doxorubicin, Journal of Nanoscience and Nanotechnology, 15, 4792, 10.1166/jnn.2015.9604 Muller, 2000, Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art, Eur J Pharm Biopharm, 50, 161, 10.1016/S0939-6411(00)00087-4 El Bahhaj, 2016, Histone Deacetylase Inhibitors Delivery using Nanoparticles with Intrinsic Passive Tumor Targeting Properties for Tumor Therapy, Theranostics, 6, 795, 10.7150/thno.13725 Torchilin, 2005, Recent advances with liposomes as pharmaceutical carriers, Nat Rev Drug Discov, 4, 145, 10.1038/nrd1632 Urbinati, 2010, Liposomes loaded with histone deacetylase inhibitors for breast cancer therapy, Int J Pharm, 397, 184, 10.1016/j.ijpharm.2010.06.046 Wang, 2014, Iron complexation to histone deacetylase inhibitors SAHA and LAQ824 in PEGylated liposomes can considerably improve pharmacokinetics in rats, J Pharm Pharm Sci, 17, 583, 10.18433/J3TS4V Abbasi, 2014, Dendrimers: synthesis, applications, and properties, Nanoscale Res Lett, 9, 247, 10.1186/1556-276X-9-247 Wang, 2009, Advances of cancer therapy by nanotechnology, Cancer Res Treat, 41, 1, 10.4143/crt.2009.41.1.1 Hu, 2010, Nanoparticle-assisted combination therapies for effective cancer treatment, Ther Deliv, 1, 323, 10.4155/tde.10.13 Zhu, 2015, Applications of Nanoparticles for Anticancer Drug Delivery: A Review, J Nanosci Nanotechnol, 15, 4753, 10.1166/jnn.2015.10298 Gothwal, 2016, Polymeric Micelles: Recent Advancements in the Delivery of Anticancer Drugs, Pharm Res, 33, 18, 10.1007/s11095-015-1784-1 Igaz, N., et al., Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures. Nanomaterials (Basel), 2020. 10(1). Goswami, 2018, Polyethylene Glycol-Encapsulated Histone Deacetylase Inhibitor Drug-Composite Nanoparticles for Combination Therapy with Artesunate, ACS Omega, 3, 11504, 10.1021/acsomega.8b02105 Bianco, 2004, Carbon nanotubes for the delivery of therapeutic molecules, Expert Opin Drug Deliv, 1, 57, 10.1517/17425247.1.1.57 Madani, 2011, A new era of cancer treatment: carbon nanotubes as drug delivery tools, Int J Nanomedicine, 6, 2963 Das, 2013, Augmented anticancer activity of a targeted, intracellularly activatable, theranostic nanomedicine based on fluorescent and radiolabeled, methotrexate-folic Acid-multiwalled carbon nanotube conjugate, Mol Pharm, 10, 2543, 10.1021/mp300701e Lay, 2010, Delivery of paclitaxel by physically loading onto poly(ethylene glycol) (PEG)-graft-carbon nanotubes for potent cancer therapeutics, Nanotechnology, 21, 10.1088/0957-4484/21/6/065101 Bhirde, 2009, Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery, ACS Nano, 3, 307, 10.1021/nn800551s Bharti, 2015, Mesoporous silica nanoparticles in target drug delivery system: A review, Int J Pharm Investig, 5, 124, 10.4103/2230-973X.160844 Desai, 2017, Lipid Bilayer-Gated Mesoporous Silica Nanocarriers for Tumor-Targeted Delivery of Zoledronic Acid in Vivo, Mol Pharm, 14, 3218, 10.1021/acs.molpharmaceut.7b00519 Gabizon, 2006, Pros and Cons of the Liposome Platform in Cancer Drug Targeting, Journal of Liposome Research, 16, 175, 10.1080/08982100600848769 Giuberti, 2011, Study of the pilot production process of long-circulating and pH-sensitive liposomes containing cisplatin, Journal of Liposome Research, 21, 60, 10.3109/08982101003754377 Wissing, 2004, Solid lipid nanoparticles for parenteral drug delivery, Advanced Drug Delivery Reviews, 56, 1257, 10.1016/j.addr.2003.12.002 Das, 2010, Recent Advances in Lipid Nanoparticle Formulations with Solid Matrix for Oral Drug Delivery, AAPS PharmSciTech, 12, 62, 10.1208/s12249-010-9563-0 Ghasemiyeh, 2018, Solid lipid nanoparticles and nanostructured lipid carriers as novel drug delivery systems: applications, advantages and disadvantages, Research in Pharmaceutical Sciences, 13, 288, 10.4103/1735-5362.235156 Freitas, 1999, Correlation between long-term stability of solid lipid nanoparticles (SLN™) and crystallinity of the lipid phase, European Journal of Pharmaceutics and Biopharmaceutics, 47, 125, 10.1016/S0939-6411(98)00074-5 Palombo, 2014, Pharmaceutical and Toxicological Properties of Engineered Nanomaterials for Drug Delivery, Annual Review of Pharmacology and Toxicology, 54, 581, 10.1146/annurev-pharmtox-010611-134615 Safari, 2014, Advanced drug delivery systems: Nanotechnology of health design A review, Journal of Saudi Chemical Society, 18, 85, 10.1016/j.jscs.2012.12.009 Svenson, 2005, Dendrimers in biomedical applications--reflections on the field, Advanced Drug Delivery Reviews, 57, 2106, 10.1016/j.addr.2005.09.018 Bamrungsap, 2012, Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system, Nanomedicine (Lond), 7, 1253, 10.2217/nnm.12.87 Duncan, 2006, Polymer conjugates as anticancer nanomedicines, Nature Reviews Cancer, 6, 688, 10.1038/nrc1958 Yokoyama, 2014, Polymeric micelles as drug carriers: their lights and shadows, Journal of Drug Targeting, 22, 576, 10.3109/1061186X.2014.934688 Biswas, 2016, Recent advances in polymeric micelles for anti-cancer drug delivery, European Journal of Pharmaceutical Sciences, 83, 184, 10.1016/j.ejps.2015.12.031 Liu, 2012, Nanomaterials for Ocular Drug Delivery, Macromolecular Bioscience, 12, 608, 10.1002/mabi.201100419 Shi, 2013, Self-assembled lipid-polymer hybrid nanoparticles for the sustained delivery of siRNA and the treatment of drug-resistant cancers, Cancer Research, 73 Dave, 2019, Lipid-polymer hybrid nanoparticles: Synthesis strategies and biomedical applications, Journal of Microbiological Methods, 160, 130, 10.1016/j.mimet.2019.03.017 Mukherjee, 2019, Lipid–polymer hybrid nanoparticles as a next-generation drug delivery platform: state of the art, emerging technologies, and perspectives, International Journal of Nanomedicine, 14, 1937, 10.2147/IJN.S198353 Hadinoto, 2013, Lipid–polymer hybrid nanoparticles as a new generation therapeutic delivery platform: A review, European Journal of Pharmaceutics and Biopharmaceutics, 85, 427, 10.1016/j.ejpb.2013.07.002 Sharma, 2017, 57 Goodman, 2017, Understanding Resonant Light-Triggered DNA Release from Plasmonic Nanoparticles, ACS Nano, 11, 171, 10.1021/acsnano.6b06510 Liang, 2014, Inorganic nanomaterials for bioimaging, targeted drug delivery and therapeutics, Chemical Communications, 50, 14071, 10.1039/C4CC03118K Dhar, 2008, Targeted Single-Wall Carbon Nanotube-Mediated Pt(IV) Prodrug Delivery Using Folate as a Homing Device, Journal of the American Chemical Society, 130, 11467, 10.1021/ja803036e Sayes, 2006, Functionalization density dependence of single-walled carbon nanotubes cytotoxicity in vitro, Toxicology Letters, 161, 135, 10.1016/j.toxlet.2005.08.011 Shvedova, 2005, Unusual inflammatory and fibrogenic pulmonary responses to single-walled carbon nanotubes in mice, American Journal of Physiology-Lung Cellular and Molecular Physiology, 289, L698, 10.1152/ajplung.00084.2005 Han, 2015, Hybrid lipid-capped mesoporous silica for stimuli-responsive drug release and overcoming multidrug resistance, ACS applied materials & interfaces, 7, 3342, 10.1021/am5082793 Ilhan-Ayisigi, 2018, Silica-based organic-inorganic hybrid nanoparticles and nanoconjugates for improved anticancer drug delivery, Engineering in Life Sciences, 18, 882, 10.1002/elsc.201800038 Ngwa, 2014, Targeted radiotherapy with gold nanoparticles: current status and future perspectives, Nanomedicine (Lond), 9, 1063, 10.2217/nnm.14.55 Hein, 2008, Click chemistry, a powerful tool for pharmaceutical sciences, Pharm Res, 25, 2216, 10.1007/s11095-008-9616-1 Bertrand, 2019, The ROMP: A Powerful Approach to Synthesize Novel pH-Sensitive Nanoparticles for Tumor Therapy, Biomolecules, 9, 10.3390/biom9020060 Gurunathan, 2018, Combination Effect of Silver Nanoparticles and Histone Deacetylases Inhibitor in Human Alveolar Basal Epithelial Cells, Molecules, 23, 10.3390/molecules23082046 Kataoka, 2001, Block copolymer micelles for drug delivery: design, characterization and biological significance, Adv Drug Deliv Rev, 47, 113, 10.1016/S0169-409X(00)00124-1 Lee, 2019, Esterase-sensitive cleavable histone deacetylase inhibitor-coupled hyaluronic acid nanoparticles for boosting anticancer activities against lung adenocarcinoma, Biomater Sci, 7, 4624, 10.1039/C9BM00895K Martin, 2013, Nanoparticles for urothelium penetration and delivery of the histone deacetylase inhibitor belinostat for treatment of bladder cancer, Nanomedicine, 9, 1124, 10.1016/j.nano.2013.05.017 Enriquez, 2013, Formulation and evaluation of drug-loaded targeted magnetic microspheres for cancer therapy, Int J Nanomedicine, 8, 1393 Ruttala, 2017, Molecularly targeted co-delivery of a histone deacetylase inhibitor and paclitaxel by lipid-protein hybrid nanoparticles for synergistic combinational chemotherapy, Oncotarget, 8, 14925, 10.18632/oncotarget.14742 Sankar, 2014, Biocompatibility and biodistribution of suberoylanilide hydroxamic acid loaded poly (DL-lactide-co-glycolide) nanoparticles for targeted drug delivery in cancer, Biomed Pharmacother, 68, 865, 10.1016/j.biopha.2014.07.015 Meng, 2013, Chitosan-based nanocarriers with pH and light dual response for anticancer drug delivery, Biomacromolecules, 14, 2601, 10.1021/bm400451v